Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to...
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical...
BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing...
Consumer-facing cannabis awards recognize the brands' 'Just Add Color' marketing campaign as the best in 2022Company’s Chief People Officer resigning...
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25,...
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in...
Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced...
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new...
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant gliomaBOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango...
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint...
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused...
Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB) The...
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
San Antonio, Texas, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Clearday, Inc. (OTCQX:CLRD) (“Clearday”, the “Company” or “we”) is pleased to...
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows...
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology...
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for...
LAFAYETTE, La., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national...
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today...